Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock
- 1 September 1995
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 15 (5) , 266-273
- https://doi.org/10.1007/bf01540884
Abstract
Interleukin-10 is a potent macrophage-deactivating cytokine that inhibits lipopolysaccharide-induced tumor necrosis factor production. We determined the plasma levels of immunoreactive interleukin-10 in 16 patients with septic shock and in 11 patients with circulatory shock of nonseptic origin. In septic shock, interleukin-10 levels peaked during the first 24 h (median: 48 pg/ml) and decreased progressively till Day 5. In nonseptic shock, interleukin-10 plasma levels also increased during the first 24 h but to a lesser extent (median: 17 pg/ml). In septic shock patients, interleukin-10 plasma levels were positively correlated with tumor necrosis factor (r=0.8,p=0.01) and with parameters of shock severity including lactate levels (r=0.56, pr=−0.65,pα and interleukin-6 afterin vitro incubation of whole blood from septic shock patients with lipopolysaccharide was not influenced byin vitro neutralization of interleukin-10. We conclude that interleukin-10 is produced in patients with circulatory shock of septic and nonseptic origin and that the production of this anti-inflammatory cytokine during septic shock correlates positively with the intensity of the inflammatory response.Keywords
This publication has 39 references indexed in Scilit:
- Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemiaEuropean Journal of Immunology, 1994
- Pathogenesis and Potential Strategies for Prevention and Treatment of Septic Shock: An UpdateClinical Infectious Diseases, 1994
- Interleukin‐10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharideEuropean Journal of Immunology, 1993
- Interleukin-10Annual Review of Immunology, 1993
- In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A.The Journal of Experimental Medicine, 1993
- Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.The Journal of Experimental Medicine, 1993
- Macrophage deactivation by interleukin 10.The Journal of Experimental Medicine, 1991
- Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.The Journal of Experimental Medicine, 1991
- Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat.Journal of Clinical Investigation, 1990
- Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.Journal of Clinical Investigation, 1988